Tanya Dinesh
Researcher
Currently working as the Lead Research Assistant on the ComCOV1/2 trials investigating the safety, reactogenicity, and immunogenicity of heterologous prime-boost COVID-19 vaccine schedules.
Recent publications
-
Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.
Journal article
Shaw RH. et al, (2023), J Infect
-
Human leukocyte antigen alleles associate with COVID-19 vaccine immunogenicity and risk of breakthrough infection.
Journal article
Mentzer AJ. et al, (2022), Nat Med
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Journal article
Shaw RH. et al, (2022), Lancet Respir Med
-
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
Journal article
Stuart ASV. et al, (2022), Lancet, 399, 36 - 49
-
AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific TH1 response with a diverse TCR repertoire.
Journal article
Swanson PA. et al, (2021), Sci Transl Med, 13